000			02100 a2200637 4500
005			20250515091429.0
264		0	_c20071220
008			200712s 0 0 eng d
022			_a0724-8741
024	7		_a10.1007/s11095-007-9433-y _2doi
040			_aNLM _beng _cNLM
100	1		_aVlugt-Wensink, K D F
245	0	0	_aPreclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation. _h[electronic resource]
260			_bPharmaceutical research _cDec 2007
300			_a2239-48 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article
650	0	4	_aAged
650	0	4	_aAnimals
650	0	4	_aBiomarkers _xblood
650	0	4	_aBody Size _xdrug effects
650	0	4	_aBody Weight _xdrug effects
650	0	4	_aChemistry, Pharmaceutical
650	0	4	_aDelayed-Action Preparations
650	0	4	_aDextrans _xchemistry
650	0	4	_aDisease Models, Animal
650	0	4	_aDrug Carriers
650	0	4	_aDrug Compounding
650	0	4	_aDwarfism _xdrug therapy
650	0	4	_aHuman Growth Hormone _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aInjections, Subcutaneous
650	0	4	_aInsulin-Like Growth Factor Binding Protein 3
650	0	4	_aInsulin-Like Growth Factor Binding Proteins _xblood
650	0	4	_aInsulin-Like Growth Factor I _xmetabolism
650	0	4	_aMale
650	0	4	_aMethacrylates _xchemistry
650	0	4	_aMice
650	0	4	_aMice, Mutant Strains
650	0	4	_aMicrospheres
650	0	4	_aMiddle Aged
650	0	4	_aModels, Biological
650	0	4	_aParticle Size
650	0	4	_aSolubility
650	0	4	_aTranscription Factor Pit-1 _xdeficiency
700	1		_ade Vrueh, R
700	1		_aGresnigt, M G
700	1		_aHoogerbrugge, C M
700	1		_avan Buul-Offers, S C
700	1		_ade Leede, L G J
700	1		_aSterkman, L G W
700	1		_aCrommelin, D J A
700	1		_aHennink, W E
700	1		_aVerrijk, R
773	0		_tPharmaceutical research _gvol. 24 _gno. 12 _gp. 2239-48
856	4	0	_uhttps://doi.org/10.1007/s11095-007-9433-y _zAvailable from publisher's website
999			_c17449986 _d17449986